Takeda Pharmaceutical

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following segments: Prescription Drug, Consumer Healthcare, and Other. The Prescription Drugs segment includes the manufacture and sale of pharmaceutical products. The Consumer Healthcare segment includes the manufacture and sale of OTC drugs and quasi-drugs. The Other segment includes manufacture and sale of reagents, clinical diagnostics, and chemical products. The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 350,000 shares of Takeda Pharmaceutical Co.

Cathie Wood's ARK Invest Sells Over 350,000 Shares of Takeda Pharma

DUBAI, UAE, June 16, 2021 /PRNewswire/ -- Takeda Pharmaceuticals Company (TSE: 4502) (NYSE: TAK) ("Takeda"), a global, values-based, R&D-driven biopharmaceutical company, headquartered in Japan, is celebrating its 240th founding anniversary in June 2021, marking a significant milestone in bringing Better Health and a Brighter Future to people worldwide. The company was first founded by Chobei Takeda in 1781 in Osaka, Japan, with the Pharmaceutical Manufacturing Business starting in 1895 and the Takeda Pharmaceutical Company established in 1915.

Takeda Pharmaceuticals Marks its 240th Founding Anniversary

One ARK Invest exchange-traded fund run by ETF star Cathie Wood sold over 225,000 shares of Takeda Pharmaceutical Co.

Cathie Wood's ARK Invest Sells Over 225,000 Shares of Takeda Pharma

DUBAI, UAE, June 9, 2021 /PRNewswire/ -- Takeda (TSE: 4502) (NYSE: TAK) has introduced the "In Their Shoes"  platform, an award-winning, immersive simulation program to promote greater awareness and empathy for patients with Inflammatory bowel disease (IBD), a condition to describe Crohn's disease and ulcerative colitis, to a group of healthcare providers in the Middle East the first time.  The subscription-based program launched with a two-day simulation where healthcare providers and Takeda employees learned about the condition most effectively and profoundly: by "living with it.

Takeda introduces the In Their Shoes experience to the Middle East in support of the IBD patient community

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today at the American Transplant Congress (ATC) 2021 Virtual Connect presented results from a new subgroup analysis of SOT recipients in the Phase 3 TAK-620-303 (SOLSTICE) trial, for the investigational drug TAK-620 (maribavir). More than twice (55.6%, 79/142) as many SOT recipients with R/R CMV infection at baseline treated with maribavir achieved confirmed CMV viremia clearance at Study Week 8

Phase 3 Clinical Trial Subgroup Analysis Across Solid Organ Transplant (SOT) Types Supports Efficacy of Maribavir Over Conventional Therapies in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)

Decibel Therapeautics

Edgewise Therapeutics

Recursion Pharmaceuticals

Is investor enthusiasm for new biotechnology companies waning? Based on the performance of the 35 biotechs that went public in the first quarter, that may be the case.

Losers Outnumber Gainers in Biotech IPOs This Year

Takeda Pharmaceutical Co Ltd (NYSE: TAK) unveiled long-term data for its dengue vaccine candidate (TAK-003), showing the shot's efficacy waned over time but that it was still “robust” in preventing hospitalization. The two-dose vaccine was 62% effective at preventing dengue infection three years after participants received the second dose, the latest data show.

Takeda's Dengue Vaccine Effective In Reducing Hospitalization Regardless Of Prior Infection

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that its dengue vaccine candidate (TAK-003) demonstrated continued protection against dengue illness and hospitalization, regardless of an individual's previous dengue exposure, with no important safety risks identified through three years after vaccination in the ongoing pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) trial. TIDES

Potential Impact of Takeda's Dengue Vaccine Candidate Reinforced by Long-Term Safety and Efficacy Results

The FDA has accepted for review Takeda Pharmaceutical Co Ltd's (NYSE TAK) marketing application for maribavir for cytomegalovirus (CMV) Infection. The application under priority review is seeking maribavir approval CMV infection in those that are refractory with or without resistance (R/R), in solid organ transplant (SOT), or hematopoietic cell transplant (HCT) recipients.

Takeda's Maribavir US Application For Post-Transplant CMV Infection Under Review

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food & Drug Administration (FDA) has accepted a New Drug Application (NDA) for maribavir for the treatment of CMV infection in those that are refractory with or without resistance (R/R), in solid organ transplant (SOT) or hematopoietic cell transplant (HCT) recipients. This is an inflection year for Takeda's pipeline with up

U.S. Food & Drug Administration Grants Priority Review of Maribavir for the Treatment of Post-Transplant Recipients With Cytomegalovirus Infection in Those Resistant and/or Refractory to Prior Anti-CMV Treatment

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the Ministry of Health, Labour and Welfare (MHLW) granted special approval under article 14-3 of the Pharmaceuticals and Medical Devices Act for emergency use of Moderna's mRNA COVID-19 vaccine, TAK-919, now known as COVID-19 Vaccine Moderna Intramuscular Injection, in Japan. The approval is based on positive clinical data from Takeda's Phase 1/2 immunogenicity and safety cli

Takeda Announces Approval of Moderna's COVID-19 Vaccine in Japan

Takeda Pharmaceuticals Inc. ( TAK , Financial) has cleared the decks and sees smoother sailing ahead. That's according to the Japanese company's CEO, Christophe Weber.

Takeda CEO Says 2021 an 'Inflection Point' for Company

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that primary analysis data from the Phase 2 OPTIC (Optimizing Ponatinib Treatment In CML) trial will be presented during an oral session at the virtual 57th American Society of Clinical Oncology (ASCO) Annual Meeting, and as an oral session at the virtual 26th European Hematology Association (EHA) Annual Meeting. The OPTIC trial is a randomized, open-label study

Takeda to Present Positive Primary Analysis from Phase 2 OPTIC Trial of ICLUSIG® (ponatinib), Reinforcing Ability to Address Gaps in Care for Chronic-Phase CML

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced updated data from the Phase 1/2 trial of mobocertinib (TAK-788) orally administered in patients with epidermal growth factor receptor (EGFR) Exon20 insertion mutation-positive (insertion+) metastatic non-small cell lung cancer (mNSCLC) who received prior platinum-based chemotherapy. The results showed mobocertinib continued to demonstrate clinically meaningful b

Takeda Presents Updated Results for Mobocertinib, Further Substantiating the Clinical Benefit in Patients with EGFR Exon20 Insertion+ mNSCLC

Cerecor

CRISPR Therapeutics

Horizon Pharma

Johnson & Johnson

Eli Lilly

Schrodinger 

Here are seven biotech stocks with loads of innovation and plenty of catalysts to make money for smart investors. The post 7 Best Biotech Stocks To Buy in 2021 as Innovation Takes Center Stage appeared first on InvestorPlace.

7 Best Biotech Stocks To Buy in 2021 as Innovation Takes Center Stage

Takeda Pharmaceutical Company Limited's (TAK) CEO Christophe Weber on Q4 2020 Results - Earnings Call Transcript

Takeda Pharmaceutical Co Ltd (NYSE: TAK) reported an FY20 net profit of ¥376 billion, a 750% Y/Y increase, reflecting gains on non-core asset sales and lower acquisition-related expenses. Takeda exceeded its $10 billion non-core asset divestiture target and has announced 12 deals since January 2019 to date for a total aggregate value of up to $12.9 billion.

Takeda FY20 Profit Surges, Revenue Drops; Guides For Weak FY21 Profit

Takeda Pharmaceutical Co on Tuesday said it may double imports of Moderna Inc's COVID-19 vaccine to help Japan speed up COVID-19 inoculation efforts that have trailed most wealthy countries.

Takeda says it may double imports of Moderna shots to help accelerate Japan vaccination

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502) (NYSE:TAK) (“Takeda”) today announced financial results for fiscal year 2020 (period ended March 31, 2021). TAKEDA PRESIDENT AND CHIEF EXECUTIVE OFFICER CHRISTOPHE WEBER commented: “Over the course of FY2020, Takeda remained resilient as we operated in new ways through the COVID-19 pandemic. This is a testament to the dedication of our employees, and Takeda's unwavering commitment to serving patients, our people,

Takeda Delivers Resilient FY2020 Results With Strong Margins & Robust Cashflow; Underlying Revenue Growth Expected to Accelerate in FY2021

Takeda Pharmaceutical (TAK) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Moving Average Crossover Alert: Takeda Pharmaceutical (TAK)

Takeda is one of the top ten biopharma companies worldwide in terms of revenue, and the number one in Asia.

Takeda: A Rare Biopharma Bargain

OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it was awarded by the International Society for Pharmaceutical Engineering (ISPE) for the 2021 Facility Of the Year Awards (FOYA) in two categories. Takeda's new solid pharmaceutical packaging building in Hikari, Japan, was recognized with the 2021 “Process Intelligence and Innovation” category award. Additionally, the end-to-end high potent drug facility in Grange Castle, Ir

Takeda Manufacturing Facilities in Japan and Ireland Recognized With Category Awards for 2021 Facilities of the Year

CAMBRIDGE, Mass. & OSAKA, Japan--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review for the company's New Drug Application (NDA) for mobocertinib (TAK-788) for the treatment of adult patients with epidermal growth factor receptor (EGFR) Exon20 insertion mutation-positive (insertion+) metastatic non-small cell lung cancer (mNSCLC), as detected by an FDA-approved test, w

Takeda Announces U.S. FDA Grants Priority Review for New Drug Application for Mobocertinib (TAK-788) as a Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer

You might want to consider adding this company to your portfolio.

Down Nearly 50% From All-Time Highs, Is This Pharma Giant a Good Buy?

Coursera

QUALCOMM

Cadence Bank

Discover

Evergy Inc

Lattice Semiconductor

Trip.com

With the trading day about halfway over, the broad markets were pulling back after setting record highs to close out last week.

News for Takeda Pharmaceutical Stock (TAK)